Autopsy report · NCT02927366
Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients
Cause of deathFunding or business
“Study was terminated early for strategic reasons. Only Part I of the study was completed.”
Life of this trial
- Registered 11 months before it started.
- Ran for about 9 months before it stopped.
- 8 participants enrolled.
- Results were posted on the registry 1 year 2 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- QCC374; Placebo Matching
- Participants
- 8
- Sites
- 5
- Countries
- Germany, South Korea, United Kingdom, United States
Trials that died the same way
- A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
“The combination part of the study was terminated early due to business reasons” - An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections
“Study was prematurely terminated due to administrative and strategic reasons” - Measuring Relative Afferent Pupillary Defect
“The study was terminated early for administrative reasons.” - PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer
“The study was terminated early due to company decision.” - LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
“Study was terminated due to slow accrual.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.